A new treatment option for adult and paediatric patients with a rare soft tissue cancer has been approved. The FDA has approved new immunotherapy drug atezolizumab (Tecentriq) for patients with advanced alveolar soft part sarcoma (ASPS) that has either spread to other parts of the body or cannot be removed by surgery for another reason.
